Comparative effectiveness of secukinumab and etanercept in biologic-naïve patients with psoriatic arthritis assessed by matching-adjusted indirect comparison

Comparative effectiveness of secukinumab and etanercept in biologic-naïve patients with psoriatic arthritis assessed by matching-adjusted indirect comparison

Bibliographic Details
Main Authors:	Philip Mease, Ernest Choy, Peter Nash, Chrysostomos Kalyvas, Matthias Hunger, Luminita Pricop, Kunal K. Gandhi, Steffen M. Jugl, Howard Thom
Format:	Article
Language:	English
Published:	AVES 2019-07-01
Series:	European Journal of Rheumatology
Online Access:	https://www.eurjrheumatol.org/eng/makale/3224/219/Full-Text

Similar Items

Clinically relevant patient clusters identified by machine learning from the clinical development programme of secukinumab in psoriatic arthritis
by: Peter Nash, et al.
Published: (2021-12-01)

Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies
by: Laura C. Coates, et al.
Published: (2019-12-01)

Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3)
by: Peter Nash, et al.
Published: (2018-03-01)

Minimal disease activity among active psoriatic arthritis patients treated with secukinumab: 2‐year results from a multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled phase III study
by: Coates, L, et al.
Published: (2018)

Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies
by: Coates, L, et al.
Published: (2019)

Effect of secukinumab on the different GRAPPA-OMERACT core domains in psoriatic arthritis: a pooled analysis of 2049 patients
by: Orbai, A-M, et al.
Published: (2019)

Secukinumab for ankylosing spondylitis and psoriatic arthritis
by: Lubrano E, et al.
Published: (2016-10-01)

Etanercept (Enbrel) in the treatment of psoriatic arthritis
by: T V Korotaeva
Published: (2009-12-01)

Quantification of pre-existing radiographic damage and its relationship with joint activity and long-term clinical outcomes with secukinumab therapy in patients with psoriatic arthritis
by: Philip Mease, et al.
Published: (2022-12-01)

RESULTS OF EVALUATING THE EFFICACY OF SECUKINUMAB VERSUS ADALIMUMAB IN TREATING PSORIATIC ARTHRITIS BY USING THE MATCHING-ADJUSTED INDIRECT COMPARISON METHOD
by: T. V. Korotaeva
Published: (2016-12-01)

Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Psoriatic Arthritis: Final 5‐year Results from the Phase 3 FUTURE 1 Study
by: Philip J. Mease, et al.
Published: (2020-01-01)

Secukinumab treatment in psoriatic patients: Italian experiences
by: Luca Idolazzi
Published: (2018-11-01)

Clinically relevant patient clusters identified by machine learning from the clinical development programme of secukinumab in psoriatic arthritis
by: Pournara, E, et al.
Published: (2021)

Comparison of remission and low disease activity states with DAPSA, MDA and VLDA in a clinical trial setting in psoriatic arthritis patients: 2-year results from the FUTURE 2 study
by: Coates, L, et al.
Published: (2020)

Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study
by: Coates, L, et al.
Published: (2018)

Secukinumab provides sustained improvement in signs and symptoms and low radiographic progression in patients with psoriatic arthritis: 2-year (end-of-study) results from the FUTURE 5 study
by: Robert Landewé, et al.
Published: (2021-08-01)

Multicenter Study of Secukinumab Survival and Safety in Spondyloarthritis and Psoriatic Arthritis: SEcukinumab in Cantabria and ASTURias Study
by: Sara Alonso, et al.
Published: (2021-05-01)

Budget impact model of secukinumab for the treatment of moderate-to-severe psoriasis, psoriatic arthritis, and ankylosing spondylitis in Italy: a cross-indication initiative
by: Colombo GL, et al.
Published: (2018-08-01)

Secukinumab in multi-failure psoriatic patients: the last hope?
by: M. Magnano, et al.
Published: (2018-08-01)

Treatment of psoriatic arthritis with secukinumab: a case series
by: Stefania Nicola, et al.
Published: (2018-11-01)

Treatment with secukinumab in multi-comorbid patients with psoriatic arthritis
by: Ombretta Viapiana, et al.
Published: (2018-12-01)

Experience in using secukinumab in patients with axial psoriatic arthritis
by: E. E. Gubar, et al.
Published: (2020-11-01)

Design and rationale of the Study of Etanercept and Methotrexate in Combination or as Monotherapy in Subjects with Psoriatic Arthritis (SEAM-PsA)
by: Mease, P, et al.
Published: (2018)

Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study
by: L. C. Coates, et al.
Published: (2018-12-01)

Is secukinumab effective for psoriatic arthritis with insufficient response to initial treatment?
by: Soledad Venegas-Iribarren, et al.
Published: (2017-12-01)

Performance of composite measures used in a trial of etanercept and methotrexate as monotherapy or in combination in psoriatic arthritis
by: Coates, L, et al.
Published: (2020)

Paradoxical flare of psoriasis, psoriatic spondyloarthritis, and psoriatic uveitis after switching from infliximab to secukinumab
by: Peiqi Su, et al.
Published: (2017-06-01)

Evaluation of effectiveness and safety of Etanercept in children with Juvenile psoriatic arthritis
by: K. V. Aleksanyan, et al.
Published: (2020-09-01)

Using etanercept to maintain remission of psoriatic arthritis during pregnancy
by: Ibrahim A Al-Homood, et al.
Published: (2014-01-01)

Etanercept-Induced Hypoglycemia in a Patient With Psoriatic Arthritis and Diabetes
by: Emily C. Pfeifer MD, et al.
Published: (2017-09-01)

Predictors of response to secukinumab in patients with psoriatic arthritis and axial manifestations: a post-hoc analysis of the MAXIMISE trial
by: Baraliakos, X, et al.
Published: (2022)

The effect of secukinumab on patient-reported outcomes in patients with active psoriatic arthritis in a randomised phase 3 trial
by: Strand, V, et al.
Published: (2022)

Predictors of response to secukinumab in patients with psoriatic arthritis and axial manifestations: a post-hoc analysis of the MAXIMISE trial
by: Laure Gossec, et al.
Published: (2022-07-01)

Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data
by: A. Deodhar, et al.
Published: (2019-05-01)

Real-world effectiveness and persistence of secukinumab in the treatment of patients with psoriatic arthritis
by: Juan José Alegre-Sancho, et al.
Published: (2023-11-01)

Interleukin 17A inhibitor secukinumab in the treatment of patients with psoriatic arthritis
by: N. A. Shostak, et al.
Published: (2022-10-01)

LP-212 SLE overlap with psoriatic arthritis successfully treated with secukinumab
by: Athina Theodoridou
Published: (2023-07-01)

Cutaneous Vasculitis with Gut Involvement During Secukinumab Treatment for Psoriatic Arthritis
by: Clara Chelli, et al.
Published: (2020-03-01)

The effect of secukinumab treatment on hematological parameters in ankylosing spondylitis and psoriatic arthritis
by: Ahmet Karataş, et al.
Published: (2020-10-01)

Real-world data on secukinumab use for psoriatic arthritis and ankylosing spondylitis
by: Ashley Elliott, et al.
Published: (2019-06-01)